We have incredible news to share! Massachusetts-based bluebird bio, a leader in the research and treatment of cancer and severe genetic diseases, just received FDA “Breakthrough Therapy” designation for their Lenti-D™ gene therapy for patients with cerebral adrenoleukodystrophy (CALD).
This designation will allow for expedited development and review of the treatment protocol, meaning it is well on its way to becoming a mainstream treatment option! We are thrilled at the progress bluebird has already made, and the positive results from the treatment study that led to this designation.
Read more about this potentially life-changing news, and join us in celebrating a major step in the treatment of ALD! Thank you, bluebird bio!
